Acucela
Acucela Highlights Data to Be Presented at ARVO
Published in Clinical Trials Week, May 11th, 2009
Data will be presented on the safety, tolerability and effectiveness of ACU-4429, a single-dose daily oral treatment for dry AMD, the most common form of the disease. All forms (wet and dry) of age-related macular degeneration affect more than 1.75 million people in the United States and are expected to increase to almost 3 million by 20201. Currently, there is no approved medicinal therapeutic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2009-05-11)
More Articles from Clinical Trials Week
- Ardea Biosciences, Inc.
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors - Breast Cancer
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial - Genta Incorporated
Genta Announces Presentations for Two Lead Compounds, Genasense® and Tesetaxel, at 2009 Annual ASCO Meeting - Isis Pharmaceuticals, Inc.
Isis and Collaborators Present New Research at the ATVB Annual Conference - Synexus
Synexus Ability to Handle the Whole of a Phase II Trial Slashes Time and Costs - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
